Boletim informativo corporativo

GEA opens a new chapter for biopharmaceutical separation processes with pharma separator lines aseptic and pure

06 Jul 2021

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Contact

Dr. Michael Golek

Media Relations

GEA Group Aktiengesellschaft

Ulmenstrasse 99


40476

Düsseldorf


Germany

+49 211 9136-0

About GEA

A GEA é uma das maiores fornecedoras para a indústria de processamento de alimentos e para uma ampla variedade de outras indústrias que geraram receitas consolidadas de aproximadamente EUR 4,9 bilhões em 2019.

Stay informed!

Are you a journalist? Then sign up to our press mailing list and select the topics you would like to be informed about

Media Relations

GEA Group Aktiengesellschaft
Ulmenstrasse 99
40476 Düsseldorf
Germany
pr@gea.com